文献速递乳腺技术与安全US

利用H扫描超声成像监测乳腺癌新辅助治疗早期反应:初步临床前结果

Monitoring Early Breast Cancer Response to Neoadjuvant Therapy Using H-Scan Ultrasound Imaging: Preliminary Preclinical Results.
PubMed 文献 · J Ultrasound Med · 2018-10-02

本研究在乳腺癌小鼠模型中评估H扫描超声成像监测新辅助治疗早期反应的价值,在给予单剂量紫杉醇或对照处理后于基线及24、48、168小时进行成像。结果显示治疗组肿瘤H扫描图像在7天内出现显著变化,且蓝色色调占比与肿瘤内凋亡活性呈显著线性相关。初步临床前结果提示H扫描超声成像可能为监测新辅助治疗早期肿瘤反应提供预后价值。

要点

  • 治疗组肿瘤H扫描图像较对照组更偏蓝色调,终止时两组差异显著(P < .05)。
  • H扫描图像蓝色色调占比与肿瘤内凋亡活性呈显著线性相关(R2 > 0.40,P < .04)。
  • H扫描超声成像可能为监测新辅助治疗早期肿瘤反应提供预后价值。

核心结论

  • 初步临床前结果提示H扫描超声成像是一种新的、有前景的组织表征方法。
  • H扫描超声成像可能在监测新辅助治疗早期肿瘤反应时提供预后价值。

研究设计与样本

  • 临床前乳腺癌动物模型研究,使用荧光素酶阳性乳腺癌荷瘤小鼠。
  • 实时H扫描超声成像在可编程超声扫描仪(Vantage 256;Verasonics Inc.,柯克兰,华盛顿州)上实现,配备L11-4v换能器。
  • 在给予单剂量新辅助治疗(紫杉醇)或对照处理后的基线及24、48、168小时进行生物发光和H扫描超声成像。
  • 动物在48或168小时安乐死,肿瘤进行组织学处理以识别癌细胞增殖和凋亡。

关键影像表现/征象

  • 对照和治疗组肿瘤的基线H扫描超声图像相当。
  • 治疗组肿瘤H扫描超声图像在7天研究期间表现出显著变化(P < .05)。
  • 终止时,对照和治疗肿瘤的H扫描超声图像之间存在显著差异(P < .05)。
  • 治疗肿瘤的H扫描超声图像比对照肿瘤图像更偏蓝色调。

诊断标准与关键数值

  • H扫描超声图像中蓝色色调占比与肿瘤内凋亡活性呈显著线性相关(R2 > 0.40,P < .04)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: H-scan imaging is a new ultrasound technique used to visualize the relative size of acoustic scatterers. The purpose of this study was to evaluate the use of H-scan ultrasound imaging for monitoring early tumor response to neoadjuvant treatment using a preclinical breast cancer animal model.

METHODS: Real-time H-scan ultrasound imaging was implemented on a programmable ultrasound scanner (Vantage 256; Verasonics Inc., Kirkland, WA) equipped with an L11-4v transducer. Bioluminescence and H-scan ultrasound was used to image luciferase-positive breast cancer-bearing mice at baseline and at 24, 48, and 168 hours after administration of a single dose of neoadjuvant (paclitaxel) or sham treatment. Animals were euthanized at 48 or 168 hours, and tumors underwent histologic processing to identify cancer cell proliferation and apoptosis.

RESULTS: Baseline H-scan ultrasound images of control and therapy group tumors were comparable, but the latter exhibited significant changes over the 7-day study (P < .05). At termination, there was a marked difference between the H-scan ultrasound images of control and treated tumors (P < .05). Specifically, H-scan ultrasound images of treated tumors were more blue in hue than images obtained from control tumors. There was a significant linear correlation between the predominance of the blue hue found in the H-scan ultrasound images and intratumoral apoptotic activity (R2 > 0.40, P < .04).

CONCLUSION: Preliminary preclinical results suggest that H-scan ultrasound imaging is a new and promising tissue characterization modality. H-scan ultrasound imaging may provide prognostic value when monitoring early tumor response to neoadjuvant treatment.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Khairalseed M, Javed K, Jashkaran G, et al. Monitoring Early Breast Cancer Response to Neoadjuvant Therapy Using H-Scan Ultrasound Imaging: Preliminary Preclinical Results. J Ultrasound Med. 2018. PMID: 30280391. doi:10.1002/jum.14806

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。